Combined treatment with tPA and butylphthalide was recently reported to reduce the incidence of HT and improve prognosis in cerebral ischemic patients, and these beneficial effects were related to the alleviation of tPA-induced neuroinflammation [24]. The gene discussed is PLAT; the disease is hematocrit.